[{"id":"b935f1d2-e009-45bc-b32a-dd41602b8dd2","acronym":"SMT-SL","url":"https://clinicaltrials.gov/study/NCT07201012","created_at":"2025-10-04T08:01:34.733Z","updated_at":"2025-10-04T08:01:34.733Z","phase":"","brief_title":"Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome","source_id_and_acronym":"NCT07201012 - SMT-SL","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" PMS2","pipe":"","alterations":" ","tags":["PMS2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-10-01"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"4574703b-19bd-4bd3-9dd9-9adace3f6487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896839","created_at":"2023-06-09T16:06:51.642Z","updated_at":"2024-07-02T16:34:27.634Z","phase":"Phase 1/2","brief_title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","source_id_and_acronym":"NCT05896839","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/11/2024","start_date":" 08/11/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"962a2b73-b00a-476e-82b6-64720adf870e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03467789","created_at":"2021-01-18T17:05:25.626Z","updated_at":"2024-07-02T16:35:06.292Z","phase":"Phase 1","brief_title":"Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma","source_id_and_acronym":"NCT03467789","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-02"},{"id":"ef5ef83b-bc3d-4dc9-9b78-e271828de65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050122","created_at":"2023-09-22T14:10:44.436Z","updated_at":"2024-07-02T16:35:08.695Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","source_id_and_acronym":"NCT06050122","lead_sponsor":"Sol-Gel Technologies, Ltd.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/17/2024","start_date":" 03/17/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"},{"id":"04584984-e8aa-4f15-9b71-d34c5c6cb62e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03816332","created_at":"2021-01-18T18:51:19.330Z","updated_at":"2024-07-02T16:35:12.938Z","phase":"Phase 1","brief_title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","source_id_and_acronym":"NCT03816332","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 10/11/2022","primary_completion_date":" 10/11/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"060e7871-5a8c-4f16-a224-6a753b1ca603","acronym":"","url":"https://clinicaltrials.gov/study/NCT05859074","created_at":"2023-05-15T14:04:26.274Z","updated_at":"2024-07-02T16:35:19.241Z","phase":"Phase 1","brief_title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05859074","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MQ710"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/04/2023","start_date":" 05/04/2023","primary_txt":" Primary completion: 05/04/2028","primary_completion_date":" 05/04/2028","study_txt":" Completion: 05/04/2028","study_completion_date":" 05/04/2028","last_update_posted":"2024-02-15"},{"id":"f9e8a0b7-2582-42c3-ba42-3a60ab5f129f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323202","created_at":"2024-01-18T18:18:19.652Z","updated_at":"2024-07-02T16:35:23.036Z","phase":"Phase 1","brief_title":"Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H\u0026N","source_id_and_acronym":"NCT04323202","lead_sponsor":"Brian Gastman","biomarkers":" CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-18"},{"id":"35641ab2-6f4d-40e3-8334-a2f46e81a6fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020912","created_at":"2021-08-25T14:53:19.986Z","updated_at":"2024-07-02T16:35:29.739Z","phase":"Phase 2","brief_title":"Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy","source_id_and_acronym":"NCT05020912","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3","pipe":" | ","alterations":" LAG3 expression","tags":["PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-11-09"},{"id":"e5c5e3c9-2ffb-460f-a19f-d1731cde39ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03897036","created_at":"2021-01-18T19:11:35.946Z","updated_at":"2024-07-02T16:35:50.335Z","phase":"Phase 1","brief_title":"Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)","source_id_and_acronym":"NCT03897036","lead_sponsor":"Senhwa Biosciences, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e silmitasertib (CX-4945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-18"},{"id":"91d5dbc6-6dcf-4eba-8db8-c5f341150900","acronym":"GEN-602-CT-101","url":"https://clinicaltrials.gov/study/NCT03775525","created_at":"2021-01-18T18:40:37.562Z","updated_at":"2024-07-02T16:35:58.589Z","phase":"Phase 1","brief_title":"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT03775525 - GEN-602-CT-101","lead_sponsor":"Genzada Pharmaceuticals USA, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • GZ17-6.02"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 127","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-12-23"},{"id":"fa288c29-592d-4dfb-ba55-267713dd3131","acronym":"DUET-2","url":"https://clinicaltrials.gov/study/NCT03517488","created_at":"2021-01-18T17:18:50.722Z","updated_at":"2024-07-02T16:35:59.763Z","phase":"Phase 1","brief_title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03517488 - DUET-2","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2022-12-01"},{"id":"2662a4c2-734b-4130-82be-9db5d81981b2","acronym":"MITOSKIN","url":"https://clinicaltrials.gov/study/NCT04389112","created_at":"2022-05-13T21:53:34.962Z","updated_at":"2024-07-02T16:36:00.024Z","phase":"","brief_title":"Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions","source_id_and_acronym":"NCT04389112 - MITOSKIN","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" CASP3 • FLG","pipe":"","alterations":" ","tags":["CASP3 • FLG"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-11-23"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"5c7c0e76-dd87-4e80-bf01-0ebe05aa6ba7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03458117","created_at":"2021-01-18T17:02:53.863Z","updated_at":"2024-07-02T16:36:15.107Z","phase":"Phase 1","brief_title":"T-VEC in Non-melanoma Skin Cancer","source_id_and_acronym":"NCT03458117","lead_sponsor":"University of Zurich","biomarkers":" CXCL11","pipe":"","alterations":" ","tags":["CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 03/15/2022","study_completion_date":" 03/15/2022","last_update_posted":"2022-03-18"},{"id":"8ab9b326-945d-42b1-83a2-bd1ce3110fd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03180528","created_at":"2021-01-18T15:41:05.915Z","updated_at":"2024-07-02T16:36:29.416Z","phase":"Phase 2","brief_title":"Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer","source_id_and_acronym":"NCT03180528","lead_sponsor":"Kavita Sarin","biomarkers":" STAT3 • GLI1","pipe":"","alterations":" ","tags":["STAT3 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e remetinostat (SHP-141)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2018","start_date":" 07/07/2018","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2021-06-08"},{"id":"d06e8af1-41a9-44ee-8b8e-7998ed004a25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703310","created_at":"2021-01-18T18:08:53.199Z","updated_at":"2024-07-02T16:36:33.679Z","phase":"Phase 3","brief_title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","source_id_and_acronym":"NCT03703310","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2021-03-08"},{"id":"8d12d438-d87a-485c-b4b4-2495d92991e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759261","created_at":"2021-02-18T23:55:24.048Z","updated_at":"2024-07-02T16:36:34.434Z","phase":"","brief_title":"SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity","source_id_and_acronym":"NCT04759261","lead_sponsor":"Trakya University","biomarkers":" SMAD4","pipe":"","alterations":" ","tags":["SMAD4"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-02-18"},{"id":"bd4e22eb-e007-4bbd-b9f9-de346b73748b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489086","created_at":"2021-01-18T01:44:50.001Z","updated_at":"2024-07-02T16:36:39.432Z","phase":"Phase 2","brief_title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","source_id_and_acronym":"NCT00489086","lead_sponsor":"UCSF Benioff Children's Hospital Oakland","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2020-10-29"},{"id":"59268b77-bb30-4adf-a5d0-4fd49befb347","acronym":"","url":"https://clinicaltrials.gov/study/NCT03714529","created_at":"2021-01-18T18:12:27.097Z","updated_at":"2024-07-02T16:36:40.289Z","phase":"Phase 2a","brief_title":"A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma","source_id_and_acronym":"NCT03714529","lead_sponsor":"Herlev and Gentofte Hospital","biomarkers":" PD-L1 • CD8","pipe":"","alterations":" ","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IO103"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 02/05/2020","primary_completion_date":" 02/05/2020","study_txt":" Completion: 02/05/2020","study_completion_date":" 02/05/2020","last_update_posted":"2020-10-08"},{"id":"c663f86c-8c21-4a7a-8e67-8631b40ab78c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04570683","created_at":"2021-01-18T21:49:37.618Z","updated_at":"2024-07-02T16:36:40.487Z","phase":"Phase 1","brief_title":"Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas","source_id_and_acronym":"NCT04570683","lead_sponsor":"Bispebjerg Hospital","biomarkers":" PD-L1 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2020-09-30"},{"id":"bb831b25-4b1e-44f8-a3dc-5bc7d5306158","acronym":"","url":"https://clinicaltrials.gov/study/NCT02354261","created_at":"2021-01-18T11:12:06.637Z","updated_at":"2024-07-02T16:36:42.308Z","phase":"Phase 2b","brief_title":"Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)","source_id_and_acronym":"NCT02354261","lead_sponsor":"HedgePath Pharmaceuticals, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/07/2015","start_date":" 08/07/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-08-05"},{"id":"6889e74c-2f8e-4b32-bd6f-76f2558287eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02157623","created_at":"2021-01-18T10:02:07.074Z","updated_at":"2024-07-02T16:36:42.587Z","phase":"","brief_title":"Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome","source_id_and_acronym":"NCT02157623","lead_sponsor":"Edward Maytin, MD, PhD","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2020-07-30"}]